Zobrazeno 1 - 10
of 44
pro vyhledávání: '"Noémie, Kraaijpoel"'
Autor:
Marte A.M. van Hylckama Vlieg, Kazem Nasserinejad, Chantal Visser, Wichor M. Bramer, Aneel A. Ashrani, Jean-Luc Bosson, Daniel J. Crusan, Andrea D'Alessio, Meg E. Fluharty, Valdis Ģībietis, Per-Olof Hansson, Nobuhiro Hara, Luis Jara-Palomares, Noémie Kraaijpoel, Isabelle Mahé, Andrea Marshall, Yutaka Ogino, Remedios Otero, Jorie Versmissen, Frederikus A. Klok, Marieke J.H.A. Kruip, Carin C.D. van der Rijt, Eric C.T. Geijteman
Publikováno v:
EClinicalMedicine, Vol 64, Iss , Pp 102194- (2023)
Summary: Background: The optimal duration of anticoagulation in patients with active cancer and venous thromboembolism (VTE) is unknown. Current clinical guidelines advocate anticoagulant therapy for 3–6 months and to continue anticoagulant therapy
Externí odkaz:
https://doaj.org/article/0b244b1247b14396920dccd8d33a5371
Autor:
Tobias Tritschler, Anuj Patel, Noémie Kraaijpoel, Deepak L. Bhatt, Giuseppe De Luca, Pietro Di Santo, Fausto Feres, Ricardo A. Costa, Benjamin Hibbert, Takaaki Isshiki, Grégoire Le Gal, Lana A. Castellucci
Publikováno v:
Research and Practice in Thrombosis and Haemostasis, Vol 6, Iss 7, Pp n/a-n/a (2022)
Abstract Background Assessment of the case‐fatality rate (CFR) of major bleeding on dual antiplatelet therapy (DAPT) may improve balancing risks and benefits of different durations of DAPT following percutaneous coronary intervention (PCI). Objecti
Externí odkaz:
https://doaj.org/article/aea6635cda6c4c25a75a2df567347ee6
Autor:
Geert-Jan Geersing, Toshihiko Takada, Frederikus A Klok, Harry R Büller, D Mark Courtney, Yonathan Freund, Javier Galipienzo, Gregoire Le Gal, Waleed Ghanima, Jeffrey A Kline, Menno V Huisman, Karel G M Moons, Arnaud Perrier, Sameer Parpia, Helia Robert-Ebadi, Marc Righini, Pierre-Marie Roy, Maarten van Smeden, Milou A M Stals, Philip S Wells, Kerstin de Wit, Noémie Kraaijpoel, Nick van Es
Publikováno v:
PLoS Medicine, Vol 19, Iss 1, p e1003905 (2022)
BackgroundThe challenging clinical dilemma of detecting pulmonary embolism (PE) in suspected patients is encountered in a variety of healthcare settings. We hypothesized that the optimal diagnostic approach to detect these patients in terms of safety
Externí odkaz:
https://doaj.org/article/957272a8001d408f9fa1a47efe2fbaf0
Autor:
Noémie Kraaijpoel, Frits I. Mulder, Marc Carrier, Annabel van Lieshout, Tom Würdinger, Myron G. Best, Bart J.M. van Vlijmen, Yassene Mohammed, Luis Jara-Palomares, Pieter W. Kamphuisen, Marcello Di Nisio, Walter Ageno, Jan Beyer-Westendorf, Thomas Vanassche, Frederikus A. Klokm, Hans-Martin Otten, Mike J.L. Peters, Benilde Cosmi, Marije ten Wolde, Patrick M.M. Bossuyt, Harry R. Büller, Nick van Es
Publikováno v:
Thrombosis Update, Vol 2, Iss , Pp 100030- (2021)
Occult cancer is detected in about 5% of patients with unprovoked venous thromboembolism (VTE) in the 12 months following VTE diagnosis. Current guidance suggests conducting a ‘limited’ cancer screening in these patients, consisting of medical hi
Externí odkaz:
https://doaj.org/article/2dd9496a84fc4b7081e92959d00b7e2f
Autor:
Noémie Kraaijpoel, Marc Carrier, Grégoire Le Gal, Matthew D F McInnes, Jean-Paul Salameh, Trevor A McGrath, Nick van Es, David Moher, Harry R Büller, Patrick M Bossuyt, Mariska M G Leeflang
Publikováno v:
PLoS ONE, Vol 15, Iss 2, p e0228788 (2020)
BACKGROUND:Compression ultrasonography (CUS) is the first-line imaging test in the diagnostic management of suspected deep vein thrombosis (DVT) of the lower extremity. Three CUS strategies are used in clinical practice. However, their relative diagn
Externí odkaz:
https://doaj.org/article/f46c3eafef2849de8765290f20024261
Autor:
Carla Schenker, Caterina E. Marx, Noémie Kraaijpoel, Grégoire Le Gal, Deborah M. Siegal, Frederikus A. Klok, Drahomir Aujesky, Tobias Tritschler
Publikováno v:
Journal of thrombosis and haemostasis, 21(6), 1553-1566. Wiley-Blackwell
Background: Fatal bleeding is a component of the primary safety outcome in most studies evaluating anticoagulation for venous thromboembolism (VTE), but a standardized definition for fatal bleeding is lacking. Objectives: To summarize definitions of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4294847d7d119d66c669d2a267493776
https://pure.amc.nl/en/publications/definitions-of-fatal-bleeding-in-clinical-studies-evaluating-anticoagulant-treatment-for-venous-thromboembolism(24cf9e49-6ade-4458-a47c-007dbfec7b1f).html
https://pure.amc.nl/en/publications/definitions-of-fatal-bleeding-in-clinical-studies-evaluating-anticoagulant-treatment-for-venous-thromboembolism(24cf9e49-6ade-4458-a47c-007dbfec7b1f).html
Autor:
Noori A.M. Guman, Thijs F. van Haaps, Nick van Es, Mariska M.G. Leeflang, Victor E.A. Gerdes, Saskia Middeldorp, Harry R. Büller, Noémie Kraaijpoel
Publikováno v:
Thrombosis Research, 216, 11-13
Thrombosis Research, 216, pp. 11-13
Guman, N A M, van Haaps, T F, van Es, N, Leeflang, M M G, Gerdes, V E A, Middeldorp, S, Büller, H R & Kraaijpoel, N 2022, ' Interrater agreement of two scales on the severity of anticoagulant-related major bleeding in patients with venous thromboembolism ', Thrombosis Research, vol. 216, pp. 11-13 . https://doi.org/10.1016/j.thromres.2022.05.013
Thrombosis Research, 216, 11-13. Elsevier Limited
Thrombosis research, 216, 11-13. Elsevier Limited
Thrombosis Research, 216, pp. 11-13
Guman, N A M, van Haaps, T F, van Es, N, Leeflang, M M G, Gerdes, V E A, Middeldorp, S, Büller, H R & Kraaijpoel, N 2022, ' Interrater agreement of two scales on the severity of anticoagulant-related major bleeding in patients with venous thromboembolism ', Thrombosis Research, vol. 216, pp. 11-13 . https://doi.org/10.1016/j.thromres.2022.05.013
Thrombosis Research, 216, 11-13. Elsevier Limited
Thrombosis research, 216, 11-13. Elsevier Limited
Item does not contain fulltext
Autor:
H. R. Büller, Annelise Segers, Michele Mercuri, Peter Verhamme, Anil Duggal, Noémie Kraaijpoel, J. I. Weitz, Manila Gaddh, Sudeep Shivakumar, N. van Es, Michael A. Grosso, Marc Carrier, Tzu-Fei Wang, Gordon Royle, M. Di Nisio, Ajay K. Kakkar, George Zhang, Frits I. Mulder, David A. Garcia, Saskia Middeldorp, Gary E. Raskob
Publikováno v:
Thrombosis research, 185, 13-19. Elsevier Limited
Background The safety and efficacy of edoxaban and dalteparin is unclear for several cancer groups. Methods We evaluated the occurrence of the primary outcome in large cancer groups. The primary outcome was the composite of recurrent VTE or major ble
Autor:
Walter Ageno, Marc Carrier, Patrick M.M. Bossuyt, Myron G. Best, Marcello Di Nisio, Frederikus A. Klokm, Mike J L Peters, Marije ten Wolde, Yassene Mohammed, Pieter Willem Kamphuisen, Thomas Wurdinger, Noémie Kraaijpoel, Benilde Cosmi, Frits I. Mulder, Annabel van Lieshout, Nick van Es, Jan Beyer-Westendorf, Hans-Martin Otten, Bart J.M. van Vlijmen, Luis Jara-Palomares, Harry R. Büller, Thomas Vanassche
Publikováno v:
Thrombosis Update, 2:100030. Elsevier BV
Thrombosis Update, Vol 2, Iss, Pp 100030-(2021)
Kraaijpoel, N, Mulder, F I, Carrier, M, van Lieshout, A, Würdinger, T, Best, M G, van Vlijmen, B J M, Mohammed, Y, Jara-Palomares, L, Kamphuisen, P W, di Nisio, M, Ageno, W, Beyer-Westendorf, J, Vanassche, T, Klokm, F A, Otten, H-M, Peters, M J L, Cosmi, B, Wolde, M T, Bossuyt, P M M, Büller, H R & van Es, N 2021, ' Novel biomarkers to detect occult cancer in patients with unprovoked venous thromboembolism : Rationale and design of the PLATO-VTE study ', Thrombosis Update, vol. 2, 100030 . https://doi.org/10.1016/j.tru.2020.100030
Thrombosis Update, Vol 2, Iss, Pp 100030-(2021)
Kraaijpoel, N, Mulder, F I, Carrier, M, van Lieshout, A, Würdinger, T, Best, M G, van Vlijmen, B J M, Mohammed, Y, Jara-Palomares, L, Kamphuisen, P W, di Nisio, M, Ageno, W, Beyer-Westendorf, J, Vanassche, T, Klokm, F A, Otten, H-M, Peters, M J L, Cosmi, B, Wolde, M T, Bossuyt, P M M, Büller, H R & van Es, N 2021, ' Novel biomarkers to detect occult cancer in patients with unprovoked venous thromboembolism : Rationale and design of the PLATO-VTE study ', Thrombosis Update, vol. 2, 100030 . https://doi.org/10.1016/j.tru.2020.100030
Occult cancer is detected in about 5% of patients with unprovoked venous thromboembolism (VTE) in the 12 months following VTE diagnosis. Current guidance suggests conducting a ‘limited’ cancer screening in these patients, consisting of medical hi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::232df4c971368cc3a7124920055a7d38
https://hdl.handle.net/11383/2151173
https://hdl.handle.net/11383/2151173
Autor:
Milou A.M. Stals, Toshihiko Takada, Noémie Kraaijpoel, Nick van Es, Harry R. Büller, D. Mark Courtney, Yonathan Freund, Javier Galipienzo, Grégoire Le Gal, Waleed Ghanima, Menno V. Huisman, Jeffrey A. Kline, Karel G.M. Moons, Sameer Parpia, Arnaud Perrier, Marc Righini, Helia Robert-Ebadi, Pierre-Marie Roy, Maarten van Smeden, Phil S. Wells, Kerstin de Wit, Geert-Jan Geersing, Frederikus A. Klok
Publikováno v:
Annals of Internal Medicine. AMER COLL PHYSICIANS
Annals of Internal Medicine
Annals of Internal Medicine
Background: How diagnostic strategies for suspected pulmonary embolism (PE) perform in relevant patient subgroups defined by sex, age, cancer, and previous venous thromboembolism (VTE) is unknown. Purpose: To evaluate the safety and efficiency of the